Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 in hepatic cirrhosis with hyperammonemia
CTR20201761Phase 2Completed
- Sponsor
- Dano Pharmaceuticals
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaquizinone in Cirrhosis, hyperammonemia, hepatic encephalopathy (HE), sponsored by Dano Pharmaceuticals. Started Sep 2020; status: completed.
02
Drugs
rifaquizinone
03
Conditions
Cirrhosishyperammonemiahepatic encephalopathy (HE)
Beyond the preview
Go deeper on CTR20201761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201761.